Blue Cross and Blue Shield of Alabama’s Telehealth and Remote Access Telemedicine policy has been updated with information about using appropriate place-of-service codes for telemedicine. Review this policy on ProviderAccess for more information – Telemedicine and Remote Access Webpage
Effective November 1, 2022 – Updated Preferred Drug Changes for Patients with PEEHIP Coverage Pegfilgrastim
Fulphila (pegfilgrastim-jmdb) is now the preferred pegfilgrastim product for PEEHIP patients.
Bevacizumab, Trastuzumab and Rituximab
Effective November 1, 2022, the following are preferred products for PEEHIP patients:
- Zirabev is the exclusive preferred bevacizumab product for oncologic indications.
- Trazimera and Ogivri are the exclusive preferred trastuzumab products.
- Ruxience and Truxima are the exclusive preferred rituximab products.
Information obtained from the latest Provider News – Thursday, Nov 17th – https://providers.bcbsal.org/portal/web/pa/news